336 related articles for article (PubMed ID: 23699676)
21. The impact of pharmacy services on opioid prescribing in dental practice.
Stewart A; Zborovancik KJ; Stiely KL
J Am Pharm Assoc (2003); 2017; 57(2S):S78-S82. PubMed ID: 28215574
[TBL] [Abstract][Full Text] [Related]
22. Pharmacists' perceptions regarding the impact of hydrocodone rescheduling on prescription volume, workflow management, and patient outcomes.
Varisco TJ; Ogunsanya ME; Barner JC; Fleming ML
J Am Pharm Assoc (2003); 2017; 57(2S):S51-S62. PubMed ID: 28292504
[TBL] [Abstract][Full Text] [Related]
23. Effect of Florida's Prescription Drug Monitoring Program and Pill Mill Laws on Opioid Prescribing and Use.
Rutkow L; Chang HY; Daubresse M; Webster DW; Stuart EA; Alexander GC
JAMA Intern Med; 2015 Oct; 175(10):1642-9. PubMed ID: 26280092
[TBL] [Abstract][Full Text] [Related]
24. Opioids and Pharmacy: PMP Extension Granted.
Berlin J
Tex Med; 2019 Aug; 115(8):22. PubMed ID: 31369140
[TBL] [Abstract][Full Text] [Related]
25. Factors associated with the use of the prescription monitoring program by prescribers and pharmacists in Texas.
Thornton JD; Varisco TJ; Downs CG
Pharmacoepidemiol Drug Saf; 2021 Apr; 30(4):492-503. PubMed ID: 33458926
[TBL] [Abstract][Full Text] [Related]
26. Promoting consistent use of prescription drug monitoring programs (PDMP) in outpatient pharmacies: Removing administrative barriers and increasing awareness of Rx drug abuse.
Norwood CW; Wright ER
Res Social Adm Pharm; 2016; 12(3):509-14. PubMed ID: 26329535
[TBL] [Abstract][Full Text] [Related]
27. State legal innovations to encourage naloxone dispensing.
Davis C; Carr D
J Am Pharm Assoc (2003); 2017; 57(2S):S180-S184. PubMed ID: 28073688
[TBL] [Abstract][Full Text] [Related]
28. Dispensing Naloxone Without a Prescription: Survey Evaluation of Ohio Pharmacists.
Thompson EL; Rao PSS; Hayes C; Purtill C
J Pharm Pract; 2019 Aug; 32(4):412-421. PubMed ID: 29478362
[TBL] [Abstract][Full Text] [Related]
29. Routine opioid outcome monitoring in community pharmacy: Pilot implementation study protocol.
Nielsen S; Kowalski M; Wood P; Larney S; Bruno R; Shanahan M; Lenton S; Dietze P; Green T; Murnion B; Ritter A
Res Social Adm Pharm; 2019 Aug; 15(8):1047-1055. PubMed ID: 30396825
[TBL] [Abstract][Full Text] [Related]
30. Educating Pharmacists on a Prescription Drug Monitoring Program.
Fleming ML; Phan Y; Ferries EA; Hatfield MD
J Pharm Pract; 2016 Dec; 29(6):543-548. PubMed ID: 25947949
[TBL] [Abstract][Full Text] [Related]
31. Update on prescription monitoring in clinical practice: a survey study of prescription monitoring program administrators.
Katz N; Houle B; Fernandez KC; Kreiner P; Thomas CP; Kim M; Carrow GM; Audet A; Brushwood D
Pain Med; 2008; 9(5):587-94. PubMed ID: 18565002
[TBL] [Abstract][Full Text] [Related]
32. Design of the POINT study: Pharmacotherapy Optimisation through Integration of a Non-dispensing pharmacist in a primary care Team (POINT).
Hazen AC; Sloeserwij VM; Zwart DL; de Bont AA; Bouvy ML; de Gier JJ; de Wit NJ; Leendertse AJ
BMC Fam Pract; 2015 Jul; 16():76. PubMed ID: 26135582
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of a pharmacist-led naloxone coprescribing program in primary care.
Cariveau D; Fay AE; Baker D; Fagan EB; Wilson CG
J Am Pharm Assoc (2003); 2019; 59(6):867-871. PubMed ID: 31466899
[TBL] [Abstract][Full Text] [Related]
34. Challenges faced with opioid prescriptions in the community setting - Australian pharmacists' perspectives.
Makdessi CJ; Day C; Chaar BB
Res Social Adm Pharm; 2019 Aug; 15(8):966-973. PubMed ID: 30819418
[TBL] [Abstract][Full Text] [Related]
35. Theoretical exploration of Tennessee community pharmacists' perceptions regarding opioid pain reliever abuse communication.
Hagemeier NE; Murawski MM; Lopez NC; Alamian A; Pack RP
Res Social Adm Pharm; 2014; 10(3):562-75. PubMed ID: 23981913
[TBL] [Abstract][Full Text] [Related]
36. Doctor hopping and doctor shopping for prescription opioids associated with increased odds of high-risk use.
Young SG; Hayes CJ; Aram J; Tait MA
Pharmacoepidemiol Drug Saf; 2019 Aug; 28(8):1117-1124. PubMed ID: 31168860
[TBL] [Abstract][Full Text] [Related]
37. Using the theory of planned behavior to examine pharmacists' intention to utilize a prescription drug monitoring program database.
Fleming ML; Barner JC; Brown CM; Shepherd MD; Strassels S; Novak S
Res Social Adm Pharm; 2014; 10(2):285-96. PubMed ID: 23816495
[TBL] [Abstract][Full Text] [Related]
38. The influence of prescription monitoring programs on chronic pain management.
Wang J; Christo PJ
Pain Physician; 2009; 12(3):507-15. PubMed ID: 19461820
[TBL] [Abstract][Full Text] [Related]
39. Addition of generic medication vouchers to a pharmacist academic detailing program: effects on the generic dispensing ratio in a physician-hospital organization.
Bhargava V; Greg ME; Shields MC
J Manag Care Pharm; 2010; 16(6):384-92. PubMed ID: 20635829
[TBL] [Abstract][Full Text] [Related]
40. Managing inappropriate use of non-prescription combination analgesics containing codeine: A modified Delphi study.
Gibbins AK; Wood PJ; Spark MJ
Res Social Adm Pharm; 2017; 13(2):369-377. PubMed ID: 27084506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
